Literature DB >> 8567109

European randomized study of screening for prostate cancer--the Rotterdam pilot studies.

F H Shröder1, R A Damhuis, W J Kirkels, H J De Koning, R Kranse, H G Nus, B G Blijenberg.   

Abstract

Five randomized pilot studies of screening for prostate cancer (PC) have been conducted in the area of Rotterdam from 1991 to 1994. The purpose of these studies was to establish the feasibility of a randomized screening protocol with PC mortality as the major end point in The Netherlands and at a European level. All procedures related to recruitment of participants, to application of the screening tests and to data collection were evaluated. Men (7,200) aged 55-74 years were invited through the Rotterdam Population Registry. The recruitment rate over the 5 pilot studies averaged 38.2% (2,747 men). Recruitment procedures proved to be relevant for establishing higher participation rates (invitation and consent by mail). The screening tests were well accepted and tolerated. The general population-based character of the sample was confirmed by studying symptoms of prostatic disease in participants and in men who refused participation. Data based on one PSA serum determination, rectal examination and transrectal ultrasonography are presented; 204/1,403 men (14.5%) had a positive screening result by either test combination and underwent biopsy. Forty-nine cancers were found in 1,403 men (3.5%); 65% of prostate cancers (17/26) identified in men who eventually underwent radical prostatectomy proved to be locally confined. From the pilot studies, we conclude that a large contribution to a European Randomized Study of Screening for Prostate Cancer (ERSPC) can be made by recruiting about 40,000 men in the area of Rotterdam. The preliminary data suggest that after confirmation of the present data during the first years in the European study, DRE and TRUS can be withheld depending on the PSA result in a large proportion of the screening population.

Entities:  

Mesh:

Year:  1996        PMID: 8567109     DOI: 10.1002/(SICI)1097-0215(19960117)65:2<145::AID-IJC4>3.0.CO;2-Z

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Patient follow up screening evaluations. Examples with regard to congenital hip dislocation and congenital heart disease.

Authors:  R E Juttmann; J Hess; G J van Oortmarssen ; P J van der Maas
Journal:  J Epidemiol Community Health       Date:  2001-02       Impact factor: 3.710

2.  Digital rectal examination in primary care is important for early detection of prostate cancer: a retrospective cohort analysis study.

Authors:  Anna Lucy Walsh; Shane W Considine; Arun Z Thomas; Thomas H Lynch; Rustom P Manecksha
Journal:  Br J Gen Pract       Date:  2014-12       Impact factor: 5.386

3.  Mass screening of prostate cancer in Changchun City of China.

Authors:  Xiaomeng Li; Itiro Tsuji; Masaaki Kuwahara; Haifeng Zhang; Hongliang Wang; Ling Zhang; Guoyi Ji; Xuejian Zhao
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

4.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen
Journal:  Lancet       Date:  2014-08-06       Impact factor: 79.321

5.  European randomized study of prostate cancer screening: first-year results of the Finnish trial.

Authors:  L Määttänen; A Auvinen; U H Stenman; S Rannikko; T Tammela; J Aro; H Juusela; M Hakama
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

6.  Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less.

Authors:  Xin Liu; Jie Tang; Xiang Fei; Qiu-Yang Li
Journal:  Iran J Public Health       Date:  2015-11       Impact factor: 1.429

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.